Treatment for comorbid borderline personality disorder and alcohol use disorders: A review of the evidence and future recommendations

Experimental and Clinical Psychopharmacology

Volumn 20, Issue 4, 2012, Pages 333-344

  Gianoli, Mayumi O ^a   Jane, J Serrita ^a   O'Brien, Erin ^a   Ralevski, Elizabeth ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alcohol dependence; Borderline personality disorder; Comorbidity; Pharmacotherapy; Psychotherapy

Indexed keywords

ACAMPROSATE; ARIPIPRAZOLE; CLOZAPINE; DISULFIRAM; FLUOXETINE PLUS OLANZAPINE; LAMOTRIGINE; METHADONE; METHYLPHENIDATE; NALTREXONE; OLANZAPINE; TOPIRAMATE;

ABUSE; AGGRESSION; ALCOHOL ABSTINENCE; ALCOHOL CONSUMPTION; ALCOHOLISM; ANGER; ARTICLE; BORDERLINE STATE; COGNITIVE THERAPY; COMORBIDITY; DRINKING BEHAVIOR; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HUMAN; OPEN STUDY; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA; SUBSTANCE ABUSE; TREATMENT OUTCOME; PERSONALITY DISORDER; REVIEW;

ALCOHOLISM; BORDERLINE PERSONALITY DISORDER; HUMANS; PERSONALITY DISORDERS;

EID: 84871916361     PISSN: 10641297     EISSN: 19362293     Source Type: Journal    
DOI: 10.1037/a0027999     Document Type: Article

References (74)

1. Albanese, M. J., Khantzian, E. J., Murphy, S. L., & Green, A. I. (1994). Decreased substance use in chronically psychotic patients treated with clozapine. American Journal of Psychiatry, 151, 780-781. Retrieved from http://ajp.psychiatryonline.org/journal.aspx?journalid=13
2. American Psychiatric Association. (2000). Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR). Washington, DC: American Psychiatric Association.
3. Anton, R. F., Kranzler, H., Breder, C., Marcus, R. N., Carson, W. H., & Han, J. (2008). A randomized, multicenter, double-blind, placebo-controlled study of the efficacy and safety of aripiprazole for the treatment of alcohol dependence. Journal of Clinical Psychopharmacology, 28, 5-12. doi:10.1097/jcp.0b013e3181602fd4
4. Ball, S. A. (1998). Manualized treatment for substance abusers with personality disorders: Dual Focus Schema Therapy. Addictive Behaviors, 23, 883-891. doi:10.1016/S0306-4603(98)00067-7
5. Ball, S. A., & Young, J. E. (2000). Dual Focus Schema Therapy for personality disorders and substance dependence: Case study results. Cognitive and Behavioral Practice, 7, 270-281. doi:10.1016/S1077-7229(00)80083-8
6. Bogenschutz, M. P., & Nurnberg, H. G. (2004). Olanzapine versus placebo in the treatment of borderline personality disorder. Journal of Clinical Psychiatry, 65, 104-109. Retrieved from http://www.psychiatrist.com/doi:10.4088/JCP.v65n0118
7. Buckley, P., Thomson, P., Way, L., & Meltzer, H. Y. (1994). Substance abuse among patients with treatment-resistant schizophrenia: Characteristics and implications for clozapine therapy. American Journal of Psychiatry, 151, 385-389. Retrieved from http://ajp.psychiatryonline.org/journal.aspx?journalid=13
8. Conrod, P. J., Castellanos-Ryan, N., & Strang, J. (2010). Brief, personality-targeted coping skills interventions and survival as a non-drug user over a 2-year period during adolescence. Archives of General Psychiatry, 67, 85-93. Retrieved from www.archgenpsychiatry.com doi:10.1001/archgenpsychiatry.2009.173
9. Conrod, P. J., Stewart, S. H., Comeau, N., & Maclean, A. M. (2006). Efficacy of cognitive-behavioral interventions targeting personality risk factors for youth alcohol misuse. Journal of Clinical Child and Adolescent Psychology, 35, 550-563. doi:10.1207/s15374424jccp3504_6
10. Conrod, P. J., Stewart, S. H., Pihl, R. O., Côté, S., Fontaine, V., & Dongier, M. (2000). Efficacy of brief coping skills interventions that match different personality profiles of female substance abusers. Psychology of Addictive Behaviors, 14, 231-242. doi:10.10374.3.231
11. Garbutt, J. C. (2009). The state of pharmacotherapy for the treatment of alcohol dependence. Journal of Substance Abuse Treatment, 36, S15-23; quiz S24-15. Retrieved from http://www.journalofsubstanceabusetreatment.com/
12. Garbutt, J. C., West, S. L., Carey, T. S., Lohr, K. N., & Crews, F. T. (1999). Pharmacological treatment of alcohol dependence: A review of the evidence. Journal of the American Medical Association, 281, 1318- 1325. doi:10.1001/jama.281.14.1318
13. Grant, B. F., Chou, S. P., Goldstein, R. B., Huang, B., Stinson, F. S., Saha, T. D., Ruan, W. J. (2008). Prevalence, correlates, disability, and comorbidity of DSM-IV borderline personality disorder: Results from the Wave 2 National Epidemiologic Survey on Alcohol and Related Conditions. Journal of Clinical Psychiatry, 69, 533-545. Retrieved from http://www.psychiatrist.com/doi:10.4088/JCP.v69n0404
14. Gregory, R. J., Chlebowski, S., Kang, D., Remen, A. L., Soderberg, M. G., Stepkovitch, J., & Virk, S. (2008). A controlled trial of psychodynamic psychotherapy for co-occurring borderline personality disorder and al cohol use disorder. Psychotherapy: Theory, Research and Practice, 45, 28-41. doi:10.1037/0033-3204.45.1.28
15. Gregory, R. J., DeLucia-Deranja, E., & Mogle, J. A. (2010). Dynamic deconstructive psychotherapy versus optimized community care for borderline personality disorder co-occurring with alcohol use disorders: A 30-month follow-up. Journal of Nervous and Mental Disease, 198, 292-298. doi:10.1097/NMD.0b013e3181d6172d
16. Gregory, R. J., & Remen, A. L. (2008). A manual-based psychodynamic therapy for treatment-resistant borderline personality disorder. Psychotherapy: Theory, Research and Practice, 45, 15-27. doi:10.1037/0033-3204.45.1.15
17. Gunderson, J. G., & Links, P. S. (2008). Borderline Personality Disorder: A clinical guide (2nd ed.). Arlington, VA: American Psychiatric Publishing, Inc.
18. Hutchison, K. E., Swift, R., Rohsenow, D. J., Monti, P. M., Davidson, D., & Almeidal, A. (2001). Olanzapine reduces urge to drink after drinking cues and a priming dose of alcohol. Psychopharmacology, 155, 27-34. Retrieved from http://jop.sagepub.com/doi:10.1007/s002130000629
19. Hutchison, K. E., Wooden, A., Swift, R. M., Smolen, A., McGeary, J., Adler, L., & Paris, L. (2003). Olanzapine reduces craving for alcohol: A DRD4 VNTR polymorphism by pharmacotherapy interaction. Neuropsychopharmacology, 28, 1882-1888. doi:10.1038/sj.npp.1300264
20. Johnson, B. A. (2004). An overview of the development of medications including novel anticonvulsants for the treatment of alcohol dependence. Expert Opinion on Pharmacotherapy, 5, 1943-1955. doi:10.1517/14656566.5.9.1943
21. Johnson, B. A., Ait-Daoud, N., Bowden, C. L., DiClemente, C. C., Roache, J. D., Lawson, K., Ma, J. Z. (2003). Oral topiramate for treatment of alcohol dependence: A randomised controlled trial. The Lancet, 361, 1677-1685. doi:10.1016/S0140-6736(03)13370-3
22. Johnson, B. A., Rosenthal, N., Capece, J. A., Wiegand, F., Mao, L., Beyers, K., Swift, R. M. (2007). Topiramate for treating alcohol dependence: A randomized controlled trial. Journal of the American Medical Association, 298, 1641-1651. doi:10.1001/jama.298.14.1641
23. Kalyoncu, A., Mirsal, H., Pektas, O., Unsalan, N., Tan, D., & Beyazyurek, M. (2005). Use of lamotrigine to augment clozapine in patients with resistant schizophrenia and comorbid alcohol dependence: A potent anti-craving effect? Journal of Psychopharmacology, 19, 301-305. doi: 10.1177/0269881105051542
24. Kranzler, H. R., Covault, J., Pierucci-Lagha, A., Chan, G., Douglas, K., Arias, A. J., & Oncken, C. (2008). Effects of aripiprazole on subjective and physiological responses to alcohol. Alcoholism: Clinical and Experimental Research, 32, 573-579. doi:10.1111/j.1530-0277.2007.00608.x
25. Lenzenweger, M. F., Lane, M. C., Loranger, A. W., & Kessler, R. C. (2007). DSM-IV personality disorders in the National Comorbidity Survey Replication. Biological Psychiatry, 62, 553-564. doi:10.1016/j.biopsych.2006.09.019
26. Lieb, K., Vollm, B., Rucker, G., Timmer, A., & Stoffers, J. M. (2010). Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials. British Journal of Psychiatry, 196, 4-12. doi:10.1192/bjp.bp.108.062984
27. Linehan, M. M., & Dimeff, L. A. (1997). Dialectical behavior therapy manual of treatment interventions for drug abusers with borderline personality disorder. Seattle, WA: University of Washington.
28. Linehan, M. M., Schmidt, H., Dimeff, L. A., Craft, J. C., Kanter, J., & Comtois, K. A. (1999). Dialectical behavior therapy for patients with borderline personality disorder and drug-dependence. American Journal on Addictions, 8, 279-292. doi:10.1080/105504999305686
29. Links, P. S., Helsegrave, R. J., Mitton, J. E., van Reekum, R., & Patrick, J. (1995). Borderline personality disorder and substance abuse: Consequences of comorbidity. Canadian Journal of Psychiatry, 40, 9-14. Retrieved from http://publications.cpa-apc.org/browse/sections/0
30. Mann, K. (2004). Pharmacotherapy of alcohol dependence: A review of the clinical data. CNS Drugs, 18, 485-504. Retrieved from http://adisonline.com/cnsdrugs/Pages/default.aspx doi:10.2165/00023210-200418080-00002
31. Martinotti, G., Di Nicola, M., Di Giannantonio, M., & Janiri, L. (2009). Aripiprazole in the treatment of patients with alcohol dependence: A double-blind, comparison trial vs. naltrexone. Journal of Psychopharmacology, 23, 123-129. doi:10.1177/0269881108089596
32. Mercer, D., Douglass, A. B., & Links, P. S. (2009). Meta-analyses of mood stabilizers, antidepressants and antipsychotics in the treatment of borderline personality disorder: Effectiveness for depression and anger symptoms. Journal of Personality Disorders, 23, 156-174. Retrieved from http://guilfordjournals.com/loi/pedi doi:10.1521/pedi.2009.23.2.156
33. Miller, F. T., Abrams, T., Dulit, R., & Fyer, M. (1993). Substance abuse in borderline personality disorder. American Journal of Drug & Alcohol Abuse, 19, 491-497. Retrieved from http://informahealthcare.com/ada doi:10.3109/00952999309001637
34. Millon, T. (1987). Manual for the Millon Clinical Multiaxial Inventory-II. 2nd ed. Minneapolis, MN: National Computer Systems.
35. Miranda, R., Jr., MacKillop, J., Monti, P. M., Rohsenow, D. J., Tidey, J., Gwaltney, C., McGeary, J. (2008). Effects of topiramate on urge to drink and the subjective effects of alcohol: A preliminary laboratory study. Alcoholism: Clinical and Experimental Research, 32, 489-497. doi:10.1111/j.1530-0277.2007.00592.x
36. Morgenstern, J., Langenbucher, J., Labouvie, E., & Miller, K. J. (1997). The comorbidity of alcoholism and personality disorders in a clinical population: Prevalence rates and relation to alcohol typology variables. Journal of Abnormal Psychology, 106, 74-84. Retrieved from http://www.apa.org/pubs/journals/abn/index.aspx doi:10.1037/0021-843X.106.1.74
37. Mutschler, J., Grosshans, M., Koopmann, A., Hermann, D., Diehl, A., Mann, K., & Kiefer, F. (2010). Supervised disulfiram in relapse prevention in alcohol-dependent patients suffering from comorbid borderline personality disorder-a case series. Alcohol and Alcoholism, 45, 146- 150. doi:10.1093/alcalc/agq001
38. Nickel, M. K., Loew, T. H., & Pedrosa Gil, F. (2007). Aripiprazole in treatment of borderline patients, part II: An 18-month follow-up. Psychopharmacology, 191, 1023-1026. doi:10.1007/s00213-007-0740-0
39. Nickel, M. K., Muehlbacher, M., Nickel, C., Kettler, C., Pedrosa Gil, F., Bachler, E., Kaplan, P. (2006). Aripiprazole in the treatment of patients with borderline personality disorder: A double-blind, placebo-controlled study. American Journal of Psychiatry, 163, 833-838. Retrieved from http://ajp.psychiatryonline.org/journal.aspx?journalid=13 doi:10.1176/appi.ajp.163.5.833
40. Nickel, M. K., Nickel, C., Kaplan, P., Lahmann, C., Muhlbacher, M., Tritt, K., Loew, T. H. (2005). Treatment of aggression with topiramate in male borderline patients: A double-blind, placebo-controlled study. Biological Psychiatry, 57, 495-499. doi:10.1016/j.biopsych.2004.11.044
41. Nickel, M. K., Nickel, C., Mitterlehner, F. O., Tritt, K., Lahmann, C., Leiberich, P. K., Loew, T. H. (2004). Topiramate treatment of aggression in female borderline personality disorder patients: A double-3blind, placebo-controlled study. Journal of Clinical Psychiatry, 65, 1515-1519. Retrieved from http://www.psychiatrist.com/doi:10.4088/JCP.v65n1112
42. Nielsen, P., Røjskjær, S., & Hesse, M. (2007). Personality-Guided Treatment for Alcohol Dependence: A Quasi-Randomized Experiment. American Journal on Addictions, 16, 357-364. doi:10.1080/10550490701525640
43. Nordholm, D., & Nielsen, B. (2007). Personality disorders among Danish alcoholics attending outpatient treatment. European Addiction Research, 13, 222-229. doi:10.1159/000104885
44. Paparrigopoulos, T., Tzavellas, E., Karaiskos, D., Kourlaba, G., & Liappas, I. (2011). Treatment of alcohol dependence with low-dose topiramate: An open-label controlled study. BMC psychiatry, 11, 41. Retrieved from http://www.biomedcentral.com/bmcpsychiatry/doi:10.1186/1471-244X-11-41
45. Paris, J. (2005). Borderline personality disorder. Canadian Medical Association Journal, 172, 1579-1583. doi:10.1503/cmaj.045281
46. Peterson, R. A., & Reiss, S. (1992). Anxiety Sensitivity Index Manual. Palos Heights, IL: International Diagnostic Systems.
47. Pinto, O. C., & Akiskal, H. S. (1998). Lamotrigine as a promising approach to borderline personality: An open case series without concurrent DSM-IV major mood disorder. Journal of Affective Disorders, 51, 333- 343. doi:10.1016/S0165-0327(99)00007-5
48. Preston, G. A., Marchant, B. K., Reimherr, F. W., Strong, R. E., & Hedges, D. W. (2004). Borderline personality disorder in patients with bipolar disorder and response to lamotrigine. Journal of Affective Disorders, 79, 297-303. doi:10.1016/S0165-0327(02)00358-0
49. Ralevski, E., Ball, S., Nich, C., Limoncelli, D., & Petrakis, I. (2007). The impact of personality disorders on alcohol-use outcomes in a pharmacotherapy trial for alcohol dependence and comorbid Axis I disorders. American Journal on Addictions, 16, 443-449. doi:10.1080/10550490701643336
50. Rubio, G., Lopez-Munoz, F., & Alamo, C. (2006). Effects of lamotrigine in patients with bipolar disorder and alcohol dependence. Bipolar Disorders, 8, 289-293. doi:10.1111/j.1399-5618.2006.00292.x
51. Rubio, G., Martinez-Gras, I., & Manzanares, J. (2009). Modulation of impulsivity by topiramate: Implications for the treatment of alcohol dependence. Journal of Clinical Psychopharmacology, 29, 584-589. doi:10.1097/JCP.0b013e3181bfdb79
52. Shea, M. T., Widiger, T. A., & Klein, M. H. (1992). Comorbidity of personality disorders and depression: Implications for treatment. Journal of Consulting and Clinical Psychology, 60, 857-868. Retrieved from http://www.apa.org/pubs/journals/ccp/index.aspx doi:10.1037/0022-006X.60.6.857
53. Siever, L. J., & Davis, K. L. (1991). A psychobiological perspective on the personality disorders. American Journal of Psychiatry, 148, 1647-1658. Retrieved from ajp.psychiatryonline.org/
54. Soler, J., Pascual, J. C., Campins, J., Barrachina, J., Puigdemont, D., Alvarez, E., & Pérez, V. (2005). Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder. American Journal of Psychiatry, 162, 1221-1224. Retrieved from http://ajp.psychiatryonline.org/journal.aspx?journalid=13 doi: 10.1176/appi.ajp.162.6.1221
55. Spielberger, C. D. (1988). State-trait anger expression inventory (STAXI), research edition. Odessa, FL: Psychological Assessment Resources.
56. Stepp, S. D., Trull, T. J., & Sher, K. J. (2005). Borderline personality features predict alcohol use problems. Journal of Personality Disorders, 19, 711-722. doi:10.1521/pedi.2005.19.6.711
57. Torgersen, S. (2009). The nature (and nurture) of personality disorders. Scandinavian Journal of Psychology, 50, 624-632. doi:10.1111/j.1467-9450.2009.00788.x
58. Torgersen, S., Kringlen, E., & Cramer, V. (2001). The prevalence of personality disorders in a community sample. Archives of General Psychiatry, 58, 590-596. Retrieved from http://archpsyc.ama-assn.org/doi:10.1001/archpsyc.58.6.590
59. Tritt, K., Nickel, C., Lahmann, C., Leiberich, P. K., Rother, W. K., Loew, T. H., Nickel, M. K. (2005). Lamotrigine treatment of aggression in female borderline-patients: A randomized, double-blind, placebo-controlled study. Journal of Psychopharmacology, 19, 287-291. doi: 10.1177/0269881105051540
60. Trull, T. J., Sher, K. J., Minks-Brown, C., Durbin, J., & Burr, R. (2000). Borderline personality disorder and substance use disorders: A review and integration. Clinical Psychology Review, 20, 235-253. doi:10.1016/S0272-7358(99)00028-8
61. van Reekum, R., Links, P. S., & Fedorov, C. (1994). Impulsivity in borderline personality disorder. In K. R. Silk (Ed.), Biological and neurobiological studies of borderline personality disorder (pp. 1-22). Washington, DC: American Psychiatric Press.
62. Vengeliene, V., Heidbreder, C. A., & Spanagel, R. (2007). The effects of lamotrigine on alcohol seeking and relapse. Neuropharmacology, 53, 951-957. doi:10.1016/j.neuropharm.2007.09.006
63. Verheul, R., Ball, S., & van den Brink, W. (1997). Substance abuse and personality disorders. In H. R. Kranzler, & B. J. Rounsaville (Eds.), Dual diagnosis and treatment: Substance abuse and comorbid medical and psychiatric disorders (pp. 317-363). New York, NY: Marcel Dekker.
64. Verheul, R., Kranzler, H. R., Poling, J., Tennen, H., Ball, S., & Rounsaville, B. J. (2000). Axis I and Axis II disorders in alcoholics and drug addicts: Fact or artifact? Journal of Studies on Alcohol, 61, 101-110. Retrieved from http://www.jsad.com/
65. Voronin, K., Randall, P., Myrick, H., & Anton, R. (2008). Aripiprazole effects on alcohol consumption and subjective reports in a clinical laboratory paradigm-possible influence of self-control. Alcoholism: Clinical and Experimental Research, 32, 1954-1961. doi:10.1111/j.1530-0277.2008.00783.x
66. Walter, M., Gunderson, J. G., Zanarini, M. C., Sanislow, C. A., Grilo, C. M., McGlashan, T. H., Skodol, A. E. (2009). New onsets of substance use disorders in borderline personality disorder over 7 years of follow-ups: Findings from the Collaborative Longitudinal Personality Disorders Study. Addiction, 104, 97-103. doi:10.1111/j.1360-0443.2008.02413.x
67. Warsi, M., Sattar, S. P., Bhatia, S. C., & Petty, F. (2005). Aripiprazole reduces alcohol use. Canadian Journal of Psychiatry, 50, 244. Retrieved from https://ww1.cpa-apc.org/Publications/Archives/CJP/2005/march2/letterWarsi.asp
68. Watt, M., Stewart, S., Birch, C., & Bernier, D. (2006). Brief CBT for high anxiety sensitivity decreases drinking problems, relief alcohol outcome expectancies, and conformity drinking motives: Evidence from a randomized controlled trial. Journal of Mental Health, 15, 683-695. doi: 10.1080/09638230600998938
69. Zanarini, M. C. (1993). Borderline personality disorder as an impulse spectrum disorder. In J. Paris, (Ed.), Borderline Personality Disorder; Etiology and Treatment (pp. 67-86). Washington, D.C.: American Psychiatric Press.
70. Zanarini, M. C., & Frankenburg, F. R. (2001). Olanzapine treatment of female borderline personality disorder patients: A double-blind, placebo-controlled pilot study. Journal of Clinical Psychiatry, 62, 849-854. Retrieved from http://www.psychiatrist.com/doi:10.4088/JCP.v62n1103
71. Zanarini, M. C., Frankenburg, F. R., Dubo, E. D., Sickel, A. E., Trikha, A., Levin, A., Reynolds, V. (1998). Axis I comorbidity of borderline personality disorder. American Journal of Psychiatry, 155, 1733-1739. Retrieved from http://ajp.psychiatryonline.org/journal.aspx?journalid=13
72. Zanarini, M. C., Frankenburg, F. R., & Parachini, E. A. (2004). A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. Journal of Clinical Psychiatry, 65, 903-907. Retrieved from http://www.psychiatrist.com/doi:10.4088/JCP.v65n0704
73. Zimmerman, M., & Coryell, W. H. (1990). Diagnosing personality disorders in the community. A comparison of self-report and interview measures. Archives of General Psychiatry, 47, 527-531. Retrieved from www.archgenpsychiatry.com doi:10.1001/archpsyc.1990.01810180027005
74. Zimmet, S. V., Strous, R. D., Burgess, E. S., Kohnstamm, S., & Green, A. I. (2000). Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: A retrospective survey. Journal of Clinical Psychopharmacology, 20, 94-98. Retrieved from http://journals.lww.com/psychopharmacology/pages/default.aspx doi: 10.1097/00004714-200002000-00016